Dupilumab (Dupixent®) For severe chronic rhinosinusitis with nasal polyposis. HTA ID: 23046

Assessment Status Rapid Review Complete
HTA ID 23046
Drug Dupilumab
Brand Dupixent®
Indication Dupilumab (Dupixent®) is indicated as an add-on therapy with intranasal corticosteroids, for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.
Assessment Process
Rapid review commissioned 25/07/2023
Rapid review completed 05/09/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dupilumab compared with the current standard of care for this indication, on the basis of the proposed price relative to currently available therapies.